SynSysNet - Synaptic Proteins Database



SynSysNet


Here, we present SynSysNet, which is based on an expert-curated list of 1.000 human genes, specific to the synapse. Information on resulting proteins, their 3D structure, binding small molecules Protein-Protein-Interactions (PPIs) and Compound-Protein-Interactions are integrated.
Proteins or Compounds can be searched at the appropriate buttons and Interactive Networks can be visualized. The point Diseases present neurological diseases, to illustrate the role of SynSysNet in the medication.

If you have any questions please feel free to contact us!

Database statistics

Genes1028
Proteins6114
PDB-structures2777
Models601
Compounds46028
Protein-Drug-Interactions69063
Protein-Protein-Interactions4638
Pathways185

Interactions

Cobweb NetworkP

What is visualized in these networks?

In these networks, synaptic interactions including drugs and proteins are displayed. Pathway information is acquired from KEGG via webservice and drug-target information is shown on top. The original HIPPIE score is integrated to indicate the confidence of interactions. Thick edges correspond to high confidence.

How can I use Cobweb?

Before you can create an "Interactive Network" you have to know the IDs of the Protein (UniProt ID) or the Drug (PubChem CID) you are interested in.
To find out the IDs go to "Search Gene/Proteine" or "Compounds". Once you have the IDs you can type in them either in the corresponding field. If you like to show more than one Protein or Drug in your Interactiv Network you can easily type in all of them just devided by a semicolon.

Compound-PPI Network

Compound-PPI Network


This compound-protein-protein interaction network shows the interactions of 1.160 compounds and 894 proteins. To create the network compounds from the database SuperTarget and connected proteins from SynSysNet were chosen. A total of 6.116 interactions (edges), thereof 4.318 PPIs and 1.798 compound-protein interactions are shown. The compound-representing circles are ruby-colored, the proteins' green and the edges between them blue.
The clusters with the same same targets were analysed and it was found that many of the compounds of one cluster belong to the same ATC-code. Those clusters were highlighted and marked with the appropiate ATC-code.

Protein of the Week:
Cystatin C

Uniprot-ID: P01034

detailed viewdownload .pdb.gz
Description
Cystatin C is an important biomarker for the kidney function and inhibitor of cysteine peptidase including cathepsins B, H, L, and S, calpains and caspases. It is expressed in all cell with a nucleus and has diverse functions like the involvement in neuronal cell apoptosis, neuronal injury-induced microglial activation and other hypothesized roles for Cystatin C (bone resorption, arterial wall). Interestingly, Cystatin C shows a five-fold higher concentration in cerebrospinal fluid (CSF), so this might be the major cysteine peptidase in central nervous system. Cystatin C was found to be involved in the nervous system diseases, Parkinsons disease and amyotrophic lateral sclerosis (ALS). Study Data identify increased plasma levels and decreased CSF levels of Cystatin C in ALS patients. In Parkinsons disease Cystatin C plays a role in the pathogenesis. Analysis revealed an elevated level of Cystatin C in injured neuronal dopaminergic (DA) rat cells and leads to an up regulation of proinflammatory cytokines and neurotoxic substances e.g. free radicals through an activation of microglial cells. That could be one part in the process of DA neurodegeneration in Parkinsons disease.

Pathway of the Dopaminergic Synapse


Pathway of the Dopaminergic Synapse
This is the KEGG pathway map of a dopaminergic synapse. The compound-target relations of SynSysNet are transfered into a cellular context. To get additional information about the targeting compounds place the mouse pointer on a synapse-specific target. In this example the D(2)-dopamine receptor target is highlighed in blue. For Parkinsons disease therapy the function of the D(2)-dopamine receptor should be enhanced by the usage of agonists (for example cabergoline or rasagiline). In other diseases, such as Schizophrenia, we want to block D(2)-dopamine receptors with antipsychotics (for example risperidonum or flurophenazine). This leads to a decreased activity of the dopaminergic system.